Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.56 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.56 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.56 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NHERF1 | O14745 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | TOP2A | P11388 | 1/20 | 0.47 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14052664 | 0.86 | PDK1 (0.58) | PDK1PDK2PDK3PDK4MAPT | |
| SCHEMBL4337810 | 0.85 | TRPV1 (0.53) | MAPTSMN1; SMN2MAPK1ALDH1A1NPC1 | |
| SCHEMBL30802742 | 0.85 | SMN1; SMN2 (0.61) | PDK1PDK2PDK3PDK4MAPT | |
| SCHEMBL27954484 | 0.85 | SMN1; SMN2 (0.61) | PDK1PDK2PDK3PDK4MAPT | |
| SCHEMBL4319038 | 0.85 | MAPT (0.64) | MAPTSMN1; SMN2MAPK1ALDH1A1NPC1 | |
| SCHEMBL1548607 | 0.83 | ALDH1A1 (0.59) | PDK1PDK2PDK3PDK4MAPT | |
| SCHEMBL2722098 | 0.83 | MAPT (0.49) | MAPTSMN1; SMN2MAPK1ALDH1A1NPC1 | |
| SCHEMBL3003205 | 0.83 | CFD (0.59) | MAPTSMN1; SMN2GAA | |
| SCHEMBL2673432 | 0.83 | NPSR1 (0.49) | MAPTSMN1; SMN2MAPK1ALDH1A1NPC1 | |
| SCHEMBL5211495 | 0.83 | PDK1 (0.55) | PDK1PDK2PDK3PDK4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787877-B2 | Antibody with non-natural amino acid introduced therein | RIKEN (JP) | 2023-10-17 | — | — | US | disclosed |
| US-11767296-B2 | Heteroaryl compounds as kinase inhibitor | FUJIAN HAIXI PHARMACEUTICALS CO., LTD (CN) | 2023-09-26 | — | — | US | disclosed |
| EP-3901162-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | AbbVie Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| US-20210107997-A1 | ANTIBODY WITH NON-NATURAL AMINO ACID INTRODUCED THEREIN | RIKEN (JP) | 2021-04-15 | — | — | US | disclosed |
| US-10906990-B2 | Antibody with non-natural amino acid introduced therein | RIKEN (JP) | 2021-02-02 | — | — | US | disclosed |
| US-20200338208-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | ABBVIE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10668167-B2 | Glucocorticoid receptor agonist and immunoconjugates thereof | ABBVIE INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190262465-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | ABBVIE INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190127488-A1 | ANTIBODY WITH NON-NATURAL AMINO ACID INTRODUCED THEREIN | RIKEN (JP) | 2019-05-02 | — | — | US | disclosed |
| EP-3464318-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | AbbVie Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
| US-7553867-B2 | Furan or thiophene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| EP-2064193-A1 | HETEROCYCLIC GPR40 MODULATORS | Amgen, Inc (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080293719-A1 | Pyridiazinone Derivatives for the Treatment of Tumours | MERCK PATENT GESELLSCHAFT (DE) | 2008-11-27 | — | — | US | disclosed |
| WO-2008110794-A1 | PIPERIDINONES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-09-18 | — | — | WO | disclosed |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | AMGEN INC. (US) | 2008-04-17 | — | — | US | disclosed |
| WO-2008030520-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20060100261-A1 | Furan or thiopene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) | 2006-05-11 | — | — | US | disclosed |
| EP-1535915-A1 | FURAN OR THIOPHENE DERIVATIVE AND MEDICINAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | PDK1 393/4885PDK2 1633/4885PDK3 1822/4885 |
| US-20200338208-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | NR3C1, NR3C2, MC2R | PDK1 3711/4885PDK2 3368/4885PDK3 3135/4885 |
| US-10668167-B2 | Glucocorticoid receptor agonist and immunoconjugates thereof | NR3C1, NR3C2, MC2R | PDK1 3711/4885PDK2 3368/4885PDK3 3135/4885 |
| US-20190127488-A1 | ANTIBODY WITH NON-NATURAL AMINO ACID INTRODUCED THEREIN | NSUN3, NSUN2, LNPEP | PDK1 4036/4885PDK2 3104/4885PDK3 3338/4885 |
| US-10906990-B2 | Antibody with non-natural amino acid introduced therein | NSUN3, NSUN2, LNPEP | PDK1 4036/4885PDK2 3104/4885PDK3 3338/4885 |
| US-20060100261-A1 | Furan or thiopene derivative and medicinal use thereof | TXN2, CYP11B2, CYP11B1 | PDK1 1681/4885PDK2 1609/4885PDK3 1805/4885 |
| US-11767296-B2 | Heteroaryl compounds as kinase inhibitor | RET, ERBB2, ABL1 | PDK1 570/4885PDK2 605/4885PDK3 638/4885 |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | GPR119, GPR55, GPR65 | PDK1 639/4885PDK2 556/4885PDK3 1088/4885 |
| US-20210107997-A1 | ANTIBODY WITH NON-NATURAL AMINO ACID INTRODUCED THEREIN | NSUN3, NSUN2, LNPEP | PDK1 4036/4885PDK2 3104/4885PDK3 3338/4885 |
| US-20190262465-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | NR3C1, NR3C2, MC2R | PDK1 3711/4885PDK2 3368/4885PDK3 3135/4885 |
| US-11787877-B2 | Antibody with non-natural amino acid introduced therein | NSUN3, NSUN2, LNPEP | PDK1 4036/4885PDK2 3104/4885PDK3 3338/4885 |
| US-20080293719-A1 | Pyridiazinone Derivatives for the Treatment of Tumours | MET, RET, ERBB2 | PDK1 29/4885PDK2 50/4885PDK3 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.